Reframe Daily: Surgery, shots, and new drugs: 5 big wins for patients this week

Reframe Daily—curated by Christin Chong (neuroscience PhD, Buddhist chaplain, healthtech strategy consultant)—delivers optimistic and credible healthtech updates you won’t find in most popular news outlets, from sources scientists and healthcare providers read and trust.

Today in one sentence: A surgery for brain-fluid buildup boosted memory and walking, a weight-loss shot worked safely in kids as young as six, a cannabis extract eased stubborn back pain, a new antibody cut sinus polyps, and a multi-cancer trial showed that DNA-matched drugs can help when other treatments fail.

Pop in the Discord to chat about health →
https://forms.gle/tN3oabFTsDF21VnS8

Weekly personal shares from Christin here →
http://christin.substack.com/

Good news: This confirms a surgery that already exists really does help people with a certain kind of dementia-like walking and thinking problem. For patients and doctors, it’s strong proof to move ahead sooner instead of waiting and getting worse.

A Randomized Trial of Shunting for Idiopathic Normal-Pressure Hydrocephalus

Market readiness: 😊😊😊😊😊 (already standard surgery in US hospitals; this trial strengthens evidence and supports immediate use). 

Good news: A proven weight-loss shot helped younger kids in a careful trial, giving families and pediatricians a new, evidence-based option when lifestyle changes aren’t enough.

Liraglutide for Children 6 to <12 Years of Age with Obesity — A Randomized Trial

Market readiness: 😊😊😊😊 (drug is already FDA-approved for teens/adults; this study could support a label expansion to younger kids, but regulators still need to decide). 

Good news: In a phase 3 study, a standardized full-spectrum cannabis extract eased chronic low back pain more than placebo—pointing to a potential new non-opioid option.

Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial

Market readiness: 😊😊😊 (late-stage data are in, but it still needs regulatory review and scheduling decisions before broad US use). 

Good news: A new antibody that blocks the airway “starter signal” TSLP shrank nasal polyps and calmed inflammation in people whose sinus disease was hard to control. That could lead to fewer surgeries and better breathing.

An anti-TSLP monoclonal antibody for uncontrolled CRSwNP: the DUBHE randomized clinical trial

Market readiness: 😊😊 (early human trial (phase 1b/2a); needs larger phase 3 studies and FDA review). 

Good news: The first randomized, multi-cancer test of matching drugs to each patient’s tumor DNA builds evidence that this precision approach can help people with advanced cancers when standard options are limited.

Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trial

Market readiness: 😊😊 (mid-stage trial across tumor types; promising, but more confirmatory studies are required before broad, routine use). 

Thank you for taking the time to take care of yourself and your loved ones.